Skip to main content

Table 1 Patient and tumor characteristics at baseline (n = 9)

From: Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial

Age, years, median (range) 72 (37–83)
Gender (male: female) 8:1
ECOG performance status
 0 1 (11%)
 1 8 (89%)
Child–Pugh score  
 5 (class A) 4 (45%)
 6 (class A) 3 (33%)
 7 (class B) 2 (22%)
Etiology of HCC
 Hepatitis B virus (HBV) 5 (56%)
 Hepatitis C virus (HCV) 1 (11%)
 Non-HBV, non-HCV 3 (33%)
BCLC staging  
 B 1 (11%)
 C 8 (89%)
Number of liver tumor(s)
 Single 6 (67%)
 Multiple 3 (33%)
Portal vein thrombosis
 Present 3 (33%)
 Absent 6 (67%)
Regional lymph node metastasis
 Present 0 (0%)
 Absent 9 (100%)
Distant metastasis
 Present 1 (11%)
 Absent 8 (89%)
Maximum diameter of liver tumor, cm, median (range) 6.6 (2.3–12.3)
RT doses, Gy, median (range) 45 (37.5–53)